PCA3 and cancer: Since the six biomarkers PMP22, GOLM1, LMTK2, EZH2, GSTP1, and PCA3 in this 8-Gene Panel exhibited most differential gene expression pattern between Gleason score >6 PCa and Gleason score ≤6 PCa in cancer tissues from TCGA patient cohort and our prostate tissue cohorts previously used, we found that a combination of these six genes as a 6-Gene Panel model improved the ability to distinguish the two groups of PCa with sensitivity of 94.47% (95% CI 97.39–91.55%), specificity of 18.18% (95% CI 28.38–7.99%), PPV of 83.15% (95% CI 87.64–78.66%), and NPV of 43.48% (95% CI 63.74–23.22%) (p < 0.001).